Loading...
•
Jun 30, 2022
Natera Q2 2022 Earnings Report
Reported strong momentum driven by record volume levels, leading to raised 2022 revenue guidance.
Key Takeaways
Natera reported a 39.6% increase in total revenues, reaching $198.2 million in Q2 2022 compared to $142.0 million in Q2 2021. The company processed approximately 499,900 tests, including 484,000 accessioned in its laboratory. They are expecting to reach a cash flow breakeven quarter by mid-2024.
Total revenues increased by 39.6% to $198.2 million compared to Q2 2021.
Product revenues increased by 39.3% to $194.6 million compared to Q2 2021.
Natera processed approximately 499,900 tests, including approximately 484,000 tests accessioned in its laboratory.
Medicare coverage received for Signatera in muscle-invasive bladder cancer.
Forward Guidance
Natera anticipates 2022 total revenue of $805 million to $825 million; 2022 gross margin to be approximately 46% to 48% of revenues; selling, general and administrative costs to be approximately $560 million to $590 million; research and development costs to be $340 million to $360 million, and net cash consumption to be $370 million to $400 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...